EMPOWER-Lung1 and 3 Squamous Subgroup Analysis: Expert Insights

Author(s):

Edgardo Santos, MD, FACP, FCCP, offers expert insights into the squamous subgroup analysis of EMPOWER-Lung1 and 3, shedding light on the implications of these data for the treatment of individuals with squamous non-small cell lung cancer (NSCLC).

EP: 1.Beamion Lung 1: Zongertinib (BI 1810631) in Advanced HER2+ NSCLC

EP: 2.Expert Analysis on Recent Developments in DESTINY-Lung01 and DESTINY-Lung02 Trials

EP: 3.Expert Perspectives on the Latest TROPION-Lung01 Data

EP: 4.EMPOWER-Lung3: Cemiplimab Plus Chemotherapy in Advanced NSCLC

Now Viewing

EP: 5.EMPOWER-Lung1 and 3 Squamous Subgroup Analysis: Expert Insights

EP: 6.Future Perspectives on the Treatment of NSCLC

This is a video synopsis/ summary of an OncLive Insights® featuring: Edgardo S. Santos, MD, FACP, FCCP.

Santos discussed a follow-up analysis focused on patients with squamous non–small cell lung cancer treated with cemiplimab, a PD-1 inhibitor. The analysis pooled data from the phase 3 EMPOWER-Lung 1 and EMPOWER-Lung 3 trials. Despite different control arms (chemotherapy vs chemotherapy plus cemiplimab), the median overall survival was consistent at 22 months with cemiplimab, either alone or added to chemotherapy, specifically in the squamous subset. The median progression-free survival also exceeded 8 months with cemiplimab in patients with squamous disease across both studies. These updated findings suggest more robust extracranial efficacy for cemiplimab among patients with squamous non–small cell lung cancer.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.